Project Grant R21CA299788
Award Date 4/1/26
Completion Date 3/31/28
Dollars Obligated $397K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Pittsburgh, PA 15222, USA
Similar Awards
- Federal Grant Award Summary The University of Pittsburgh received a $408,829 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) effective June 1, 2025, through May 31, 2027. This award supports the development of positive allosteric modulators (PAMs) targeting XCR1, a chemokine receptor expressed on conventional dendritic cells subtype 1 (CDC1s). The research will utilize DNA-encoded library (DEL) technology and cryo-electron...
- Federal Grant Award Summary The National Cancer Institute awarded the University of Pittsburgh a $151,920 Project Grant under the Cancer Biology Research program (CFDA 93.396) effective September 1, 2025, through August 31, 2027. This award supports fundamental research to develop and validate Nuclear Magnetic Resonance (NMR) strategies for investigating allosteric inhibitor binding effects on Src-family kinases implicated in acute myeloid leukemia (AML). The research aims to characterize...
- Federal Grant Award Summary The University of Pittsburgh received a $169,982 Project Grant from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398) awarded August 8, 2025, through July 31, 2030. The Program in Cancer Training and Education (PICTE) initiative provides comprehensive research training and professional development services for undergraduate students pursuing careers in cancer research. The award funds a 10-week intensive summer research program...
- Federal Project Grant Award Summary The University of Pittsburgh received a $261,662 Project Grant from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398), awarded December 1, 2025, with completion targeted for April 16, 2029. This award supports an integrated in silico and in vivo genetic screening research initiative designed to identify subtype-specific hepatocellular carcinoma (HCC) genetic dependencies. The project addresses a significant clinical...
- Federal Grant Award Summary The National Cancer Institute awarded the University of Pittsburgh a $141,566 Project Grant on March 24, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support biomedical research training and career development in cancer research. The grant funds research focused on understanding the conformational landscape and regulation of small GTPases (SMGs), specifically examining how oncogenic RhoA proteins function in cancer cell environments. The project...
- Federal Project Grant Award Summary The University of Pittsburgh received a $408,829 Project Grant from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396), effective September 1, 2025 through August 31, 2027. This award supports the development of an integrative framework for surface protein imputation in spatial biology applications. The project delivers machine learning (ML) methodologies and computational tools designed to predict surface protein abundance...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded the University of Pittsburgh a Project Grant totaling $649,620 (awarded May 1, 2026; completion April 30, 2031) under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct research on Medicare Advantage insurance impacts on cancer care access and outcomes. The research will analyze coverage patterns and care quality for beneficiaries with the four most prevalent cancers—breast, colorectal, lung,...
- Federal Grant Award Summary The University of Pittsburgh has received a $121,857 Project Grant from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398) effective August 1, 2025, through July 31, 2027. This award supports a K99/R00 Pathway to Independence research project investigating how anti-cancer drugs modulate T cell activity within the tumor microenvironment to overcome immune checkpoint blockade (ICB) resistance. The research delivers three integrated...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the University of Pittsburgh a Project Grant of $658,492 under the Cancer Treatment Research program (CFDA 93.395) to develop and evaluate a novel targeted combinatorial therapy for advanced castration-resistant prostate cancer (ACRPC). The research, spanning from March 18, 2026 through February 28, 2031, focuses on optimizing the combination of CHK1 inhibitor SRA737 and WEE1 inhibitor AZD1775 to exploit the G2/M...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the University of Pittsburgh a $657,776 Project Grant under the Cancer Treatment Research program (CFDA 93.395) beginning August 1, 2025, and extending through May 31, 2030. This award supports the development of highly tumor-selective pan RAS inactivators to address oncogenic RAS-driven cancers, which account for approximately 46% of all human malignancies. The project addresses a significant clinical challenge: while...